🔴 Adaptive Biotechnologies is trading 4.7% down today on wider-than-expected GAAP loss despite raised guidance

Adaptive Biotechnologies is trading at $21.51 (4.7% down) in pre-market after reporting a wider-than-expected GAAP loss per share in its Q2 2026 earnings release.

• The company reported solid Minimal Residual Disease (MRD) revenue growth and raised its full-year MRD guidance.
• Pre-market weakness reflects investors digesting a mixed earnings profile, balancing higher losses against a strong topline and improved outlook.